Literature DB >> 2703611

High prevalence of myocardial monoclonal antimyosin antibody uptake in patients with chronic idiopathic dilated cardiomyopathy.

D Obrador1, M Ballester, I Carrió, L Bernà, G Pons-Lladó.   

Abstract

Monoclonal antimyosin antibody studies were undertaken to assess the presence of myocardial uptake in patients with chronic idiopathic dilated cardiomyopathy. Three groups were studied: 17 patients with chronic (greater than 12 months) idiopathic dilated cardiomyopathy, 12 patients with a large, poorly contracting left ventricle not due to dilated cardiomyopathy (control patients) and 8 normal individuals. The patients in the cardiomyopathy and control groups showed a similar degree of clinical and functional impairment. Imaging was undertaken 48 h after antimyosin injection. The heart/lung ratio of antimyosin uptake was used to assess the results. The mean ratio in the cardiomyopathy group was 1.83 +/- 0.36 (range 1.40 to 2.80), a value significantly higher than that obtained in the control patients without cardiomyopathy (mean 1.46 +/- 0.04, range 1.38 to 1.50) or normal subjects (mean 1.46 +/- 0.13, range 1.31 to 1.6) (p less than 0.01). No difference in the ratio was noted between the normal subjects and control patients. Abnormal antimyosin uptake was seen in 12 (70%) of the 17 patients with cardiomyopathy and in only 1 (8%) of the 12 control patients. Positive monoclonal antimyosin antibody studies are highly prevalent in chronic idiopathic dilated cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703611     DOI: 10.1016/0735-1097(89)90303-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  14 in total

1.  Doxorubicin cardiotoxicity detected by indium 111 myosin-specific imaging.

Authors:  J Lekakis; N Vassilopoulos; H Psichoyiou; P Athanassiadis; S Gerali; P Kostamis; S Moulopoulos
Journal:  Eur J Nucl Med       Date:  1991

Review 2.  Clinical role of indium-111 antimyosin imaging.

Authors:  S Bhattacharya; A Lahiri
Journal:  Eur J Nucl Med       Date:  1991

Review 3.  Radionuclide noninvasive evaluation of heart failure beyond left ventricular function assessment.

Authors:  Albert Flotats; Ignasi Carrió
Journal:  J Nucl Cardiol       Date:  2009-02-27       Impact factor: 5.952

Review 4.  Antibody imaging in the evaluation of cardiovascular diseases.

Authors:  B A Khaw; J Narula
Journal:  J Nucl Cardiol       Date:  1994 Sep-Oct       Impact factor: 5.952

5.  Clinical future of antimyosin imaging in noncoronary heart disease.

Authors:  I Carrió; M Ballester
Journal:  J Nucl Cardiol       Date:  1995 Mar-Apr       Impact factor: 5.952

6.  Antimyosin antibody imaging in experimental aortic regurgitation.

Authors:  P Lu; P Zanzonico; S M Goldfine; R Hardoff; N Magid; R Gentile; E M Herrold; J S Borer
Journal:  J Nucl Cardiol       Date:  1997 Jan-Feb       Impact factor: 5.952

Review 7.  Scintigraphic detection of inflammatory heart disease.

Authors:  A J Morguet; D L Munz; H Kreuzer; D Emrich
Journal:  Eur J Nucl Med       Date:  1994-07

8.  111Indium antimyosin antibody imaging of primary myocardial involvement in systemic diseases.

Authors:  L Sarda; P Assayag; E Palazzo; D Vilain; L Guillevin; M Faraggi; O Meyer; D Le Guludec
Journal:  Ann Rheum Dis       Date:  1999-02       Impact factor: 19.103

9.  Quantitative 111In antimyosin antibody imaging to predict the age of myocardial infarction.

Authors:  S Bhattacharya; R Senior; X J Liu; D Jain; A Lahiri
Journal:  Int J Card Imaging       Date:  1992

10.  Technetium-99m antimyosin antibody (3-48) myocardial imaging: human biodistribution, safety and clinical results in detection of acute myocardial infarction.

Authors:  R Taillefer; L Boucher; R Lambert; J Grégoire; D C Phaneuf; H Sikorsa
Journal:  Eur J Nucl Med       Date:  1995-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.